Latest Healthcare News

Cleo Diagnostics (ASX:COV) posted a 48% jump in annual loss to $5.9 million amid key progress in its ovarian cancer diagnostic test, including completion of a pivotal US trial and preparations for FDA 510(k) submission.

Excite Technology Services (ASX: EXT) has secured $3.122 million in sales over June and July 2026, bolstered by government contracts and private sector recurring revenue. The company is also tapping into a growing AI cybersecurity market with a pipeline exceeding $200,000.

Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.

Emyria has cleared a key operational hurdle by resolving Authorised Prescriber capacity constraints in Perth and Queensland, enabling a planned expansion of treatment days in Q4 2026 through the recruitment of 15 new therapists.

Memphasys has cleared a key regulatory hurdle in Vietnam for its Felix™ System, prompting a significant first commercial cartridge order and marking early clinical success in a fast-growing fertility market.

Dexus (ASX: DXS) reported steady FY26 results with AFFO of 45.0 cents per security and distributions of 37.0 cents, while initiating a strategic review of infrastructure funds following an adverse APAC court judgment.

NAOS Emerging Opportunities Company Limited (ASX: NCC) delivered a robust FY26 with a 2416% surge in after-tax profit and an 18.7% portfolio return, outperforming the benchmark by over 10%. The company raised its fully franked dividend by 5%, signaling confidence amid a challenging market.

BLIS Technologies has kicked off FY27 with a 42% revenue increase and a return to EBITDA profitability, driven by strong B2B growth in Asia Pacific and China.

Artrya Limited marked its first full year of US commercial operations with a $25.18 million loss, driven by regulatory clearances, customer contracts, and an $80 million capital raise.

ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.

Healius Limited posted a modest revenue increase and underlying loss improvement for FY26, overshadowed by a substantial non-cash goodwill impairment and ongoing sector pressures.

AVITA Medical's PermeaDerm biosynthetic wound matrix delivers clinical outcomes on par with allograft while slashing treatment costs by 70%, according to a new multicenter study.